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1. Abstract 
The Wnt/ β-catenin signalling pathway is involved in the regulation of a multitude of cellular 
processes by controlling the concentration of the transcriptional regulator ȕ-catenin. 
Proteasomal degradation of β-catenin is mediated by the two β-transducin repeat-containing 
protein (β-TrCP) paralogues HOS and FWD1, which are functionally interchangeable and 
thereby considered to function redundantly in the pathway. HOS and FWD1 are ERth 
regulated by Wnt/ β-catenin signalling, albeit in opposite directions, thus establishing 
interlocked negative and positive feedback loops. The functional relevance of the opposite 
regulation of HOS and FWD1 by Wnt/ β-catenin signalling in conjunction with their redundant 
activities in proteasomal degradation of β-catenin is an unresolved issue. Using a detailed 
ordinary dierential equation (ODE) model, we investigated the specic inuence of each 
individual feedback mechanism and their combination on Wnt/ β-catenin signal transduction 
under wild type and cancerous conditions. We found that under wild type conditions the 
signalling dynamics are predominantly aected by the HOS feedback due to a higher 
concentration of HOS than FWD1. Transcriptional up-regulation of FWD1 by other signalling 
pathways reduced the impact of the HOS feedback. The opposite regulation of HOS and 
FWD1 expression by Wnt/ β-catenin signalling allows employing the FWD1 feedback as a 
compensation mechanism against aberrant pathway activation due to reduced HOS 
concentration. In contrast, the FWD1 feedback provides no protection against aberrant 
activation in APC mutant cancer cells. 
 
2. Introduction 
The Wnt/ β-catenin signalling pathway plays central roles in many key cellular processes 
such as cell proliferation and dierentiation, mainly by exerting tight control on gene 
expression [1-3]. To achieve this, Wnt/ β-catenin signalling needs to eectively regulate the 
concentration and the activity of the transcriptional regulator β-catenin [4, 5]. In resting cells, 
the concentration of unbound β-catenin remains low because its permanent production is 
counterbalanced by its continuous degradation. The degradation is primarily mediated by a 
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destruction complex [6]. In this complex, axis inhibition protein (Axin) and adenomatous 
polyposis coli protein (APC) form a scaold that allows casein kinase 1 (CK1) and glycogen 
synthase kinase 3 (GSK3) to sequentially phosphorylate β-catenin at specic serine and 
threonine residues. Phosphorylated β-catenin is ubiquitinated and subsequently degraded 
by the 26S proteasome. Wnt ligands stimulate cells by binding to the cell surface receptor 
Frizzled and its co-receptors low-density lipoprotein (LDL) receptor-related 
protein 5/6 (LRP5/6) [7, 8]. Subsequently, the signal mediator Dishevelled (Dsh) is activated 
leading to a partial inhibition [9, 10] of β-catenin phosphorylation in the destruction complex 
by a yet unresolved mechanism [6, 11, 12]. As a result, β-catenin accumulates in the cytosol 
and translocates into the nucleus. There it interacts with transcription factors of the T-cell 
factor/lymphoid enhancer factor (TCF) family to regulate target gene expression [3, 13]. 
Aberrant activation of Wnt/ β-catenin signalling is found in several human diseases such as 
neurodegenerative diseases, type II diabetes, and colon cancer and is often associated with 
mutations in pathway components [14, 15]. For instance, truncation mutations of APC are 
frequently detected in colon cancer samples [15, 16]. Wnt/ β-catenin signalling has been 
subject to several mathematical modelling approaches exploiting the interrelation between 
transcriptional and adhesive functions of β-catenin, the consequences of carcinogenic 
mutations of pathway components or subcellular compartmentalisation [17-21].  
Ubiquitination of β-catenin is mediated by β-Transducin repeat-containing proteins ( β-TrCP) 
[5, 22] for which in mammalian cells two paralogues, β-TrCP1 and β-TrCP2, with high 
sequence similarity exist [23, 24] (alternatively referred to as FWD1 and Homologous to 
Slimb (HOS), respectively [4, 25, 26]). The β-TrCP paralogues constitute the F-box protein 
subunit of Skp/Cullin/F-box(SCF)-type E3 ubiquitin ligase complexes that mediates the 
substrate specicity in the ubiquitination process [27-29].  The observed lethality upon 
simultaneous deletion of both FWD1 and HOS in mice [21, 30] underscores their importance 
for proper control of β-catenin degradation and, consequently, Wnt/ β-catenin signalling. 
Generally, FWD1 and HOS are considered to be functionally redundant in regulatingȕ -
catenin stability [24-26, 31]. This notion has been inferred from (i) identical biochemical 
properties of the paralogues [26, 30], (ii) their apparent reciprocal substitution in paralogue-
specic small interfering RNA (siRNA)-mediated knock-down experiments [31], and (iii) the 
viability of FWD1 knock-out mice [26, 31, 32]. Nonetheless, the potential advantage that the 
presumed functional redundancy could oer is still debated [30]. 
Compensation by one β-TrCP paralogue for the loss of the other could explain the absence 
of phenotypic changes upon single knock-out of either the FWD1 or HOS gene in many 
tissues. However, the testis provides an example where this compensatory mechanism 
seemingly does not work [31, 33]. Precisely what determines whether or not FWD1 and HOS 
can substitute for each other is not yet known but context-dependent dierences in the 
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 expression and regulation of FWD1 and HOS could play a role. Both β-TrCP paralogues are 
thought to be expressed at low levels [25] in cell-type specific patterns: HOS is the 
predominant paralogue found in wild type tissues [25, 34, 35], whereas FWD1 is 
predominantly detected in primary tumours and cancer cell lines. In addition, HOS and 
FWD1 expression is controlled by the Wnt/β-catenin signalling pathway itself [34, 36-38], 
albeit in opposite ways. The expression and activity of HOS is directly inhibited by Wnt/β-
catenin signalling [34]. In contrast, FWD1 is up-regulated in response to Wnt/β-catenin 
signalling via an indirect mechanism: its mRNA is protected from degradation by the coding 
region determinant-binding protein (CRD-BP), which by itself is a direct target gene product 
of Wnt/β-catenin signalling [36-38]. Thus, the two β-TrCP paralogues may establish 
interlocked positive and negative feedback loops. Furthermore, besides Wnt/β-catenin 
signalling, other signalling pathways have been reported to change the expression levels of 
the two β-TrCP paralogues [36, 39-41]. Although, control of FWD1 and HOS expression 
levels by Wnt/β-catenin signalling or other signalling pathways is considered to be a very 
important factor in the regulation of Wnt/β-catenin signalling [25, 30, 36], cellular FWD1 or 
HOS concentrations have not yet been quantified. Taken together, the phenotypic 
consequences of FWD1 and HOS single knock-outs and the cellular responses to Wnt 
stimulation could be influenced by (i) differential expression of the two paralogues in different 
tissues under wild-type and pathological conditions, (ii) by the interlocked positive and 
negative feedback loops established by HOS and FWD1, and (iii) by the cross-regulation of 
FWD1 and HOS expression levels by other signalling pathways. However, the significance 
of these regulatory mechanisms and their potential impact on Wnt/β-catenin signalling 
dynamics and FWD1 and HOS knock-out phenotypes has not yet been investigated.  
Here, we have taken a mathematical modelling approach to address the issues. We extend 
a detailed kinetic model [9] by the two transcriptional feedback mechanisms acting via HOS 
as well as via CRD-BP and FWD1 to explore the potential impact of differential expression 
levels and feedback strengths on the dynamics of Wnt/β-catenin signalling. This approach 
allowed to dissect the specific effects of each individual feedback and demonstrates that 
predominantly the HOS feedback affects Wnt/β-catenin signalling dynamics in wild type cells 
while the FWD1 feedback can establish a compensation mechanism to prevent strong β-
catenin up-regulation in case of reduced HOS concentration. The presented model thus 
provides a unifying theoretical framework that allows integrating all the available 
experimental results and the proposed molecular mechanisms from separate investigations. 
The model furthermore shows that the FWD1 feedback provides no protection against 
aberrant Wnt/β-catenin pathway activation in APC mutant cancer cells indicating that 
pharmaceutical up-regulation of β-TrCP paralogues is unlikely to represent an effective 
treatment strategy. 
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3. Results 
3.1 Development of a Wnt/β-catenin pathway model that includes the 
FWD1 and HOS feedback mechanisms 
To investigate the regulatory impact of the two transcriptional feedback mechanisms acting 
via HOS and FWD1, a detailed model of the Wnt/β-catenin signalling pathway [9], which 
describes the temporal behaviour of the concentrations of central pathway components 
using ordinary differential equations (ODEs), is modified and extended. A schematic 
representation of the resulting feedback model is shown in Figure 1. In the scheme, the 
reactions marked in black are those adopted from the published model of Wnt/β-catenin 
signalling; the reactions marked in green and blue indicate the newly introduced HOS and 
FWD1 feedback mechanisms, respectively. The HOS and FWD1 feedback mechanisms are 
implemented such that FWD1 is indirectly up-regulated by Wnt/β-catenin signalling via the 
induction of CRD-BP, whereas the transcription of HOS is directly inhibited by the β-
catenin/TCF complex. The HOS and FWD1 mediated process of β-catenin ubiquitination is 
explicitly incorporated into the destruction core cycle of the extended model (Figure 1, 
reactions 10, 10b, 22, and 22b). The originally published model limits the possible β-
catenin/TCF complex concentration by a conservation relation of TCF. To lift this restriction, 
production and degradation processes of TCF are introduced (reactions 31 and 32, 
respectively). The resulting model consists of 20 ODEs and three conservation relations  
(Equations [1] – [23], supplementary Doc. S1, Section 2). A detailed description, motivation 
and discussion of the model structure are provided in Section 1.1 in the supplementary 
Doc. S1. 
The transcription of HOS mRNA (reaction 18 in Figure 1) and degradation of FWD1 
mRNA (reaction 27) are modelled by rate equations that include inhibitory 
terms (Equations [42] and [53], supplementary Doc. S1, Section 2). The corresponding 
inhibition constants ki and ki2 modulate the repressive impact of the β-catenin/TCF complex 
on HOS mRNA production and of CRD-BP on FWD1 mRNA degradation, respectively. 
Therefore, the inverse of ki is defined as the HOS feedback strength; likewise, the inverse of 
ki2 is defined as FWD1 feedback strength. For each feedback, it holds that an increasing 
inhibition constant lowers the repressive impact and thus reduces the feedback strength. 
To parameterise the model, several parameters are directly adopted from the originally 
published model of the Wnt/β-catenin signalling pathway [9] (Tables S2-S3, supplementary 
Doc. S1). Most remaining parameters are either set to values published in the literature or 
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estimated from published experimental data (further details in supplementary Doc. S1, 
Section 1.3).  For a few parameters of the reactions involved in the HOS and FWD1 
feedback mechanisms no estimates could be deduced from literature. They are set in such a 
way that the following three experimental observations are obeyed. First, both β-TrCP 
paralogues have identical biochemical properties in controlling β-catenin stability [26, 31, 
32]. Second, both β-TrCP paralogues are expressed at low levels [25]. Third, parameters 
were chosen such that the reported relative expression patterns of both β-TrCP paralogues 
in wild type and tumour tissues [25, 34, 35] are reproduced in model simulations. To validate 
this specification, steady state concentrations of FWD1 and HOS are calculated under wild 
type and APC mutant conditions. To model APC mutations, parameter sets for 13 different 
APC mutants (referred to as “m1” to “m13”) have been proposed [18]. They are considered 
to represent different realisations of APC truncation mutations that were detected in colon 
cancer samples [42, 43]. To simulate one representative mutant condition in the feedback 
model, the parameter set of APC mutant “m7” (Table S4, supplementary Doc. S1) is chosen. 
The comparison of the calculated steady state concentrations of FWD1 and 
HOS (Figure 2A) confirms a lower expression of FWD1 compared to HOS under wild type 
condition (6.7·10-3 nM and 9.1·10-2 nM, respectively) but lower expression of HOS than 
FWD1 under APC mutant condition (3.0·10-5 nM and 1.0·10-1 nM, respectively). In these 
calculations, a representative HOS and FWD1 feedback strength of 0.6 nM-1 is considered. 
Other feedback strengths ranging from 0.1 nM-1 to 6 nM-1 were also used in simulations and 
yielded similar results for the representative APC mutant condition “m7” as well as other 
APC truncation mutations (Figure 2B). This shows that the feedback model qualitatively 
reproduces the differential expression patterns of HOS and FWD1. Whether these predicted 
concentrations of HOS or FWD1 also meet measured values of cellular concentrations 
needs to be validated in future experiments. The reference parameter set as well as a 
detailed explanation of the model parameterisation considering wild type and APC mutant 
conditions are provided in Section 1.3 of supplementary Doc. S1. 
In order to investigate signal transduction dynamics of the Wnt/β-catenin signalling pathway, 
a transient Wnt stimulus is assumed in the model (Equation [61], supplementary Doc. S1), 
since it has been argued that pathway activation in vivo is transient, likely due to receptor 
inactivation or other signal down-regulating processes [9, 44-46]. In the model, a transient 
Wnt stimulus implicates that the steady state upon stimulation is equal to the initial 
unstimulated steady state (see supplementary Doc. S1, Section 1.4). 
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3.2 Variation of feedback strength allows for feedback-specific 
modulation of HOS or FWD1 expression 
To dissect the individual impact of each feedback, an influence of the respective other 
feedback needs to be prevented. This is accomplished by strongly increasing the associated 
inhibition constant. In the extreme case that an inhibition constant approaches infinity, the 
limit of the corresponding feedback strength is zero. Consequently, changes in the 
concentration of the β-catenin/TCF complex (or CRD-BP) have no impact on the 
concentrations of HOS mRNA (or FWD1 mRNA) under the respective condition. To facilitate 
numerical calculations in the model analysis, the rate equations of reactions 18 
and 27 (Equations [42] and [53], respectively, supplementary Doc. S1) are substituted by 
Equations [43] and [54], respectively, which is equivalent to setting the respective feedback 
strength to zero. In Equations [43] and [54], HOS and FWD1 expression is independent of 
changes in the concentration of the β-catenin/TCF complex and, in consequence, the 
concentrations of HOS or FWD1 stay at their initial steady state values. That means that the 
respective feedback regulation is disabled if the corresponding feedback strength is set to 
zero. 
At first, the influence of the individual feedback strengths on the steady state concentration 
of HOS and FWD1 is analysed under wild type conditions. Therefore, two cases are 
considered. First, the HOS feedback strength is varied and the FWD1 feedback strength is 
set to zero (referred to as scenario I); second, the HOS feedback strength is set to zero and 
the FWD1 feedback strength is varied (referred to as scenario II). The simulations of 
scenario I show that increasing HOS feedback strength decreases the steady state 
concentration of HOS (Figure 3A) due to the repressive impact of β-catenin/TCF on the 
production of HOS mRNA. In scenario II, increasing FWD1 feedback strength increases the 
steady state concentration of FWD1 (Figure 3B) due to the positive regulation of FWD1 by 
the β-catenin/TCF complex. In both scenarios (I and II) a variation of feedback strength does 
not change the steady state concentration of the respective other β-TrCP paralogue. 
The analysis demonstrates that variation of the individual feedback strength allows for 
feedback-specific modulation of either HOS or FWD1 expression if the respective other 
feedback strength is set to zero. Note that the steady state concentrations of HOS and 
FWD1 differ considerably (1.6 nM and 5.2·10-6 nM, respectively) if the respective feedback 
strength is set to zero. In the following sections, the individual impacts of the HOS and 
FWD1 feedbacks on the β-catenin/TCF complex, as the transcriptionally active readout of 
the pathway model, are investigated. 
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3.3 HOS feedback strength affects β-catenin/TCF steady state 
concentration and its dynamics upon Wnt stimulation 
To investigate the impact of the HOS feedback on the steady state concentration of the β-
catenin/TCF complex, scenario I is examined again. The simulations show that HOS 
feedback strengths of less than 1 nM-1 maintain a low steady state concentration of the β-
catenin/TCF complex of about 6.9 nM, whereas HOS feedback strengths greater than 1 nM-1 
result in an accumulation of β-catenin/TCF complexes (Figure 4A). As shown in Figure 3A, 
increasing HOS feedback strengths reduce the HOS protein concentration. Consequently, 
the HOS-dependent β-catenin degradation is strongly inhibited resulting in the accumulation 
of β-catenin/TCF complexes up to a concentration of about 390 nM. In the intermediate 
range of HOS feedback strength (about 1 - 10 nM-1), multiple β-catenin/TCF steady state 
solutions are possible (Materials and Methods). An analysis of the stability of the steady 
state solutions reveals that only the highest β-catenin/TCF concentration belongs to the 
stable solution observable in experiments (Materials and Methods). Thus, the steady state 
concentration of the β-catenin/TCF complex changes in a switch-like manner to alterations in 
HOS feedback strength. This implies in particular, that the steady state concentration of the 
β-catenin/TCF complex is strongly increased even in the absence of any Wnt stimulus if the 
HOS feedback strength exceeds a critical value. 
The HOS feedback strength also affects the dynamics of the β-catenin/TCF complex upon 
transient Wnt stimulation (Figure 4B). To quantify the impact of the HOS feedback strength 
on the dynamics, three measures are considered (see Materials and Methods Section 4.2) 
that characterise typical properties of transient signal-response dynamics: signalling time, 
signal duration as well as signal amplitude [47]. The signalling time may be interpreted as 
the expected time that the signal of the Wnt stimulus needs to arrive at the level of the β-
catenin/TCF complex in the pathway [48]. Signal duration refers to the duration of the β-
catenin/TCF complex concentration change upon transient Wnt stimulation and signal 
amplitude to the magnitude of the concentration change [48]. These three measures are 
calculated for the dynamics of the β-catenin/TCF complex upon transient Wnt stimulation 
considering HOS feedback strengths ranging from 10-2 nM-1 to 1 nM-1 (Figure 4C). The 
values of signalling time, signal duration, and signal amplitude for the HOS feedback 
strength of 10-2 nM-1 are very similar to those values calculated if both feedback strengths 
are set to zero (430 min, 434 min, and 2.9 nM, respectively). If the HOS feedback strength is 
increased to 1 nM-1, the signalling time increases about 2.4-fold, β-catenin/TCF signal 
duration extends about 1.8-fold, and β-catenin/TCF signal amplitude enhances by about 
40% (Figure 4C). Addressing HOS feedback strengths above 1 nM-1, the high steady state 
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concentration of the β-catenin/TCF complex (Figure 4A) is maintained over time upon 
transient Wnt stimulation (shown for a representative HOS feedback strength of 60 nM-1 in 
Figure 6A). This indicates that HOS feedback strengths above 1 nM-1 render the β-
catenin/TCF complex non-responsive to Wnt stimulation. 
Taken together, enhancing HOS feedback strengths up to 1 nM-1 leads to a low steady state 
concentration of the β-catenin/TCF complex but increases signalling time, signal duration as 
well as signal amplitude of the β-catenin/TCF complex dynamics upon transient Wnt 
stimulation. If the HOS feedback strength exceeds 1 nM-1, the steady state concentration of 
the β-catenin/TCF complex is high independent of a Wnt stimulus and does not change 
upon transient Wnt stimulation. 
3.4 FWD1 feedback strength does not affect the dynamics of the β-
catenin/TCF complex for the presumed HOS expression level 
To determine the regulatory influence of the FWD1 feedback on the β-catenin/TCF 
dynamics, scenario II is revisited. Although variation of the FWD1 feedback strength 
changes FWD1 concentration (Figure 3B), no influence of the FWD1 feedback strength on 
the steady state concentration of the β-catenin/TCF complex is observed (Figure 5A). 
Furthermore, β-catenin/TCF dynamics in response to transient Wnt stimulation appear 
unaffected by changes of FWD1 feedback strength in the range from 10-2 nM-1 to 1 nM-
1
 (Figure 5B). Signalling time, signal duration, and signal amplitude of the β-catenin/TCF 
complex dynamics stay almost constant at 430 min, 434 min, and 2.9 nM, 
respectively (Figure 5C). This insensitivity of the β-catenin/TCF complex dynamics towards 
changes in the FWD1 feedback strength is due to the constant HOS concentration of about 
1.6 nM. This HOS concentration compensates for the low FWD1 concentrations (less than 
1.1·10-2 nM) in the case of FWD1 feedback strengths of less than 1 nM-1 (Figure 3B). In the 
case of FWD1 feedback strengths above 10 nM-1, increased FWD1 concentrations (higher 
than 0.1 nM) in addition to the HOS concentration of about 1.6 nM do also not affect β-
catenin/TCF dynamics (Figure 5C). 
The analysis shows that the HOS concentration in scenario II is too high to observe effects 
of changes in FWD1 feedback strength. Since increasing HOS feedback strength reduces 
HOS concentrations (Figure 3A), different combinations of HOS and FWD1 feedback 
strength are addressed in the next section to examine a potential influence of FWD1 
feedback strength under conditions of reduced HOS expression. 
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3.5 The FWD1 feedback influences steady state concentration and 
dynamics of the β-catenin/TCF complex in the case of reduced HOS 
expression 
To investigate whether an impact of the FWD1 feedback strength becomes observable 
under the condition of reduced HOS expression, the HOS feedback strength is set to 60 nM-
1
. As demonstrated before, combining this HOS feedback strength with a FWD1 feedback 
strength of zero results in a strong increase of the steady state concentration of the β-
catenin/TCF complex (Figure 4A and Figure 6B), which is maintained over time upon 
transient Wnt stimulation (Figure 6A). If, however, this HOS feedback strength of 60 nM-1 is 
combined with a FWD1 feedback strength of 60 nM-1, the steady state concentration of the 
β-catenin/TCF complex decreases to 6.9 nM (Figure 6B), which is equal to the steady state 
concentration of the β-catenin/TCF complex corresponding to HOS feedback strengths of 
less than 1 nM-1 (Figure 4A). Moreover, setting both feedback strengths to 60 nM-1 restores 
the transient increase of the β-catenin/TCF complex concentration upon transient Wnt 
stimulation (Figure 6C), which is otherwise not observable for HOS feedback strengths of 
60 nM-1 if the FWD1 feedback strength is set to zero (Figure 6A). 
Additional simulations that consider different combinations of HOS and FWD1 feedback 
strengths below 1 nM-1 also demonstrate that increasing FWD1 feedback strengths can 
reduce the impact of the HOS feedback strength on the dynamics of the β-catenin/TCF 
complex (Fig. S1). Increasing HOS feedback strength up to 1 nM-1 approximately doubles 
the signalling times from 430 min to 890 min, increases the signal durations from 434 min to 
696 min, and enhances the signal amplitudes from 2.9 nM to 4.0 nM (Fig. S1D-F, 
respectively). These influences of the HOS feedback strength are partially counteracted by 
FWD1 feedback strengths up to 1 nM-1, reducing signalling time, signal duration, and signal 
amplitude to intermediate values (Fig. S1D-F, respectively). 
The analysis shows that the effects of the HOS feedback strength on the β-catenin/TCF 
complex can be counteracted by enhanced FWD1 feedback strength demonstrating that the 
impact of FWD1 feedback strength becomes observable under the condition of reduced 
HOS expression. 
3.6 Up-regulation of FWD1 or HOS expression level reduces the effects of 
the HOS feedback on β-catenin/TCF complex dynamics 
In the previous sections, the expression level of FWD1 was increased by enhancing FWD1 
feedback strength (Figure 3B), which describes its regulation dependent on Wnt/β-catenin 
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signalling. However, experiments indicate that the expression level of FWD1 may also be 
enhanced by stress-induced c-Jun N-terminal kinase (JNK) signalling or Akt/Protein Kinase 
B (PKB) signalling. In the feedback model, FWD1 concentration can be increased in a β-
catenin/TCF-independent manner by increasing the FWD1 mRNA production rate v28. The 
simulations show that a higher FWD1 mRNA production rate decreases signalling time, 
signal duration, and signal amplitude of the dynamics of the β-catenin/TCF complex upon 
transient Wnt stimulation (Figure 7A, dark red line) compared to the dynamics corresponding 
to the reference FWD1 mRNA production rate (red line). For example, a 10-fold increase of 
the FWD1 mRNA production rate leads to a decrease of the signalling time by about 15%, of 
the signal duration by about 10%, and of the signal amplitude by about 5% (Figure 7B, dark 
red lines). 
Considering HOS expression, simulations show that a higher HOS mRNA production rate 
vmax18 decreases signalling time, signal duration, and signal amplitude of the β-catenin/TCF 
dynamics upon transient Wnt stimulation to a larger extent compared to FWD1 (Figure 7A, 
orange line). Already a small increase of HOS mRNA production rate by only 2-fold results in 
about 14% decrease of the signalling time, about 8% decrease of signal duration, and about 
6% decrease of the signal amplitude (Figure 7B, orange lines). In the extreme case of 
transcriptional up-regulation of FWD1 and/or HOS of greater than 10-fold, signalling time, 
signal duration, and signal amplitude of the β-catenin/TCF complex dynamics decrease to 
the values of the dynamics with HOS and FWD1 feedback strengths set to zero (430 min, 
434 min, and 2.9 nM, respectively; Fig. S2). This indicates that transcriptional up-regulation 
of FWD1 or HOS in a β-catenin/TCF-independent manner reduces the impact of the HOS 
feedback on the dynamics of the β-catenin/TCF complex upon transient Wnt stimulation. 
3.7 The FWD1 feedback mechanism does not protect against up-
regulation of β-catenin/TCF complex concentrations induced by APC 
mutations 
So far, the impact of the FWD1 and HOS feedback has been discussed in the case of wild 
type cells that are characterised by a much lower concentration of FWD1 than of HOS. The 
analyses have shown that under wild type conditions the potential impact of the FWD1 
feedback on the steady state concentration and dynamics of the β-catenin/TCF complex is 
masked by the present HOS concentration. In contrast to wild type cells, primary tumours 
and cancer cell lines hardly express HOS [25, 35]. Thus, FWD1 feedback effects might 
become observable under that condition. To simulate cancerous conditions, published 
parameter sets of APC truncation mutants [18] were adopted within the feedback 
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model (supplementary Doc. S1, Section 1.3). The simulations show that the steady state 
concentrations of the β-catenin/TCF complex are increased in all APC mutants compared to 
wild type condition if the FWD1 feedback strength is set to zero in combination with a HOS 
feedback strength between 0.1 nM-1 and 1 nM-1 (Figure 8A). To explore whether the FWD1 
feedback might provide a protection mechanism against aberrant activation of Wnt/β-catenin 
signalling in cells harbouring an APC mutation, the FWD1 feedback is set to feedback 
strengths in the range of 0.1 nM-1 to 6 nM-1. The simulations show that the steady state 
concentration of FWD1 for each APC mutant condition is increased compared to its steady 
state concentration under wild type conditions, despite the absence of a Wnt 
stimulus (Figure 8C). Dependent on the particular APC mutant, the fold increase of FWD1 
spans from merely 1.1-fold for APC mutant “m1” to approximately 17-fold for APC mutants 
“m9” to “m13” (Figure 8D). Calculating the corresponding steady state concentration of the 
β-catenin/TCF complex for the wild type and each APC mutant shows that the steady state 
concentrations of the β-catenin/TCF complex hardly change if the FWD1 feedback strength 
is set in the range of 0.1 nM-1 to 6 nM-1 (Figure 8B) compared to those concentrations 
calculated for the FWD1 feedback strength set to zero (Figure 8A). This is also observed for 
other combinations of parameter values than the particular values published for APC 
truncation mutants “m1” to “m13” (Fig. S3). Taken together, the results indicate that the 
FWD1 feedback mechanism probably does not protect against up-regulated steady state 
concentration of the β-catenin/TCF complex due to mutations of APC. 
4. Discussion 
Transcriptional regulation of the expression of the β-TrCP paralogues HOS and FWD1 by 
Wnt/β-catenin signalling realises two transcriptional feedback mechanisms in the Wnt/β-
catenin pathway. In this study, the regulatory impact of the HOS and FWD1 feedbacks on 
the dynamics of Wnt/β-catenin signalling was investigated. The modelling approach allowed 
the discrimination between the particular influences of each individual feedback by 
modulating its respective feedback strength. The analysis demonstrated that the opposite 
regulation of HOS and FWD1 expression levels by the β-catenin/TCF complex results in 
distinct regulatory influence of the two feedbacks on the dynamics of the β-catenin/TCF 
complex. It furthermore showed that the actual impact of each feedback strongly depends on 
the expression levels of HOS and FWD1. 
The presented feedback model is derived from a model that quantitatively reproduced 
experimental data [9]. Since currently available information on HOS and FWD1 considered 
in our modelling approach is qualitative, the presented results should also be understood as 
qualitative. Most model parameters were set to values collected in an extensive literature 
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search. They originate from mammalian cell types as well as from extracts of Xenopus 
oocytes, since no comprehensive experimental time series data sets are available to 
estimate the kinetic parameters of a specific mammalian cell type. Recent experiments on 
the quantification of pathway components in resting mammalian cells show that key 
components such as Axin, APC, and β-catenin may be expressed in a highly cell-type 
specific manner [49-53], which may have consequences on signalling dynamics and 
downstream gene expression. From this point of view, a comprehensive quantitative 
analysis of the Wnt/β-catenin pathway would be desirable. Irrespective of this, the feedback 
model presented here accurately reproduces experimental data (Figure 2A). Comprehensive 
variations of multiple model parameters in the simulations lead to similar results 
demonstrating that the model predictions are largely independent from the particular choice 
of the model parameter set. 
In wild type cells, higher concentrations of HOS than of FWD1 have been detected [25, 34, 
35]. On the basis of this experimental finding, the model predicts that under wild type 
conditions primarily the HOS feedback influences the dynamics of the β-catenin/TCF 
complex in response to transient Wnt stimulation. Increasing HOS feedback strengths up to 
1 nM-1 increased the signalling time, signal duration, and amplitude of the dynamics of the β-
catenin/TCF complex upon transient Wnt stimulation (Figure 4B and C), which indicates a 
change in the response of the Wnt/β-catenin pathway to Wnt stimulation. Increasing HOS 
feedback strengths above 1 nM-1 increased the steady state concentration of the β-
catenin/TCF complex in a switch-like manner (Figure 4A). In that case, a Wnt stimulus does 
not induce an observable concentration change of the β-catenin/TCF complex (Figure 6A). 
This indicates that HOS feedback strengths above 1 nM-1 render the β-catenin/TCF complex 
concentration non-responsive to Wnt stimulation. To experimentally validate the predictions 
one could try to vary HOS feedback strength by modulating the transcriptional efficiency of 
the β-catenin/TCF complexes. This could be achieved by applying decoy 
oligonucleotides [54]. Decoy oligonucleotides are short synthetic double-stranded DNA 
molecules that can competitively inhibit the interaction of TCF with promoters and thus 
modulate target gene expression. In the case of HOS mRNA, decoy oligonucleotides could 
therefore reduce the inhibitory impact of β-catenin/TCF complexes on HOS mRNA 
expression. The model analysis predicts that titration of decoy oligonucleotides affects the 
dynamics of the β-catenin/TCF complex upon transient Wnt stimulation (Figure 4B and C). 
This may be best observed in CRD-BP knock-out cells since in these cells regulation of 
FWD1 by β-catenin/TCF is abolished. Thus, CRD-BP knock-out cells represent the scenario 
of FWD1 feedback strength set to zero. In CRD-BP knock-out cells, the titration of decoy 
oligonucleotides in combination with siRNA-mediated HOS knock-down (FA) may also be 
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used to experimentally validate the switch-like response of the β-catenin/TCF steady state 
concentration predicted by the model (Figure 4A). 
The model furthermore predicted that the FWD1 feedback by itself cannot influence the β-
catenin/TCF dynamics in wild type cells due to the reported HOS expression levels that by 
themselves already ensure adequate β-catenin degradation independent of the present 
FWD1 concentration (Figure 5). This result is in line with the reported experimental 
observation that already about 10-20% of the cellular HOS concentration can compensate 
even extreme variations in FWD1 concentration [33]. The model analysis showed that the 
FWD1 feedback gained regulatory impact on steady state concentration and dynamics of the 
β-catenin/TCF complex under the condition of further reduced HOS concentration (Figure 6). 
HOS feedback strengths above 1 nM-1 strongly reduce the steady state concentrations of 
HOS (Figure 3A). Such a reduced HOS concentration interferes with the degradation of β-
catenin via the HOS-dependent mechanism resulting in the strong increase of β-catenin/TCF 
concentrations if the FWD1 feedback strength is set to zero (Figure 4A and Figure 6B). If, 
however, the FWD1 feedback strength is increased to a value above zero, enhanced β-
catenin/TCF complex concentrations up-regulate the FWD1 concentration. This allows for 
enhanced β-catenin degradation via the β-catenin*/APC*/Axin*/GSK3/FWD1 complex. 
Consequently, the concentration of the β-catenin/TCF complex is reduced. Moreover, the 
pathway becomes responsive to Wnt stimulation again (Figure 6). In the same way, the 
FWD1 feedback may constitute a compensation mechanism against strong up-regulation of 
β-catenin/TCF complex concentrations due to sequestration of HOS by other substrates 
such as proteins of the IκB family. The different functions of the FWD1 and HOS feedback 
mechanisms can be experimentally tested by comparing the effects of single knock-out of 
FWD1 or HOS in wild type, CRD-BP knock-out (FWD1 feedback strength set to zero), and 
APC mutant cells (FB). Effects of HOS knock-out are compensated in wild type cells (FB, 
third bar) through the FWD1 feedback mechanism. If, however, this feedback mechanism is 
lost, as in CRD-BP knock-out cells, the absence of HOS results in a strong increase of β-
catenin/TCF concentrations (sixth bar). In contrast, knock-out of FWD1 hardly affects β-
catenin/TCF concentrations in both wild type and CRD-BP knock-out cells since their HOS 
levels are sufficient to regulate β-catenin concentrations (second and third bar). 
Experiments have shown that a knock-down of HOS as well as a knock-out of FWD1 results 
in almost no observable differences in the murine phenotypes [31]. In terms of the model this 
means that the steady state and the dynamics of the β-catenin/TCF complex are almost 
unchanged compared to the wild type condition. The modelling approach demonstrates that 
two different underlying reasons account for the experimental observations. On the one 
hand, the down-regulation of the HOS concentration by siRNA treatment is counteracted by 
the concurrent up-regulation of FWD1 induced by β-catenin/TCF. On the other hand, in the 
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case of the FWD1 knock-down, its loss is masked by the high concentration of HOS. Hence, 
under both conditions an adequate amount of total β-TrCP (HOS and FWD1) is available to 
mediate the degradation of β-catenin and to prevent effects on the phenotype. Experiments 
with FWD1 knock-out mice have demonstrated that the expression levels of HOS differ in 
different tissues. In the testis it is low compared to other tissues and the testis is the only 
tissue that shows phenotypic changes in FWD1 knock-out mice [31, 33]. The modelling 
approach indicates that if the concentration of HOS is below a critical value, it is not able to 
compensate for the loss of FWD1 resulting in a higher level of β-catenin/TCF and 
consequently a phenotypic change. Hence, the model supports the idea that the appearance 
or non-appearance of a phenotypic effect in FWD1 knock-out mice is caused by the different 
expression levels of HOS [31, 33]. 
HOS and FWD1 establish interlocked positive and negative feedback loops in Wnt/β-catenin 
signalling. Interlocked feedback loops are common network topologies in many biological 
processes. They are for instance found in the galactose utilization network of 
S. cerevisiae [55], enable stochastic fate decisions in sporulation of B. subtilis [56], underlay 
target gene regulation by Wnt signalling in C. elegans [57], are present in p53 signalling [58] 
and cell cycle regulation networks [59]. Extensive theoretical analyses on dynamical 
properties of such interlocked feedbacks have been undertaken [60-63]. These studies 
revealed a diverse set of complex dynamics, covering bistability, excitability, as well as limit-
cycle oscillations, and design principles to regulate noise depending on the considered 
biological processes. The HOS and FWD1 interlocked feedback loops reveal the additional 
property of a protection mechanism against aberrant pathway activation caused by reduced 
HOS or FWD1 activity as explained above. 
Several human diseases are associated with aberrant activation of Wnt/β-catenin signalling. 
Despite extensive research, drugs that inhibit aberrant pathway activation are not yet 
available for clinical use. This is partially due to the lack of accessible enzyme targets in the 
pathway and the complexity of pathway regulation [14, 64]. In principle, the β-TrCP 
paralogues could represent useful pharmacological tools to reduce aberrant pathway 
activation due to their capability to directly target β-catenin and promote its degradation. 
Indeed, overexpression of FWD1 was shown to promote the down-regulation of β-catenin in 
cancer cell lines [65]. The model analyses also support that notion by demonstrating that (i) 
the modulation of HOS and FWD1 expression has a strong regulatory impact on the 
dynamics of Wnt/β-catenin signalling (Figure 7), and (ii) increased FWD1 concentrations 
reduced the high β-catenin/TCF concentration that resulted from strong HOS feedbacks 
under wild type conditions (Figure 6B). 
A clinically relevant disease that is associated with aberrant activation of Wnt/β-catenin 
signalling is colon cancer. Colon cancer cells often harbour mutations in APC that reduce the 
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efficiency of β-catenin phosphorylation in the destruction complex. Simulations of APC 
mutations using the feedback model of Wnt/β-catenin signalling showed that the mutation-
induced increase of the steady state concentration of β-catenin/TCF is paralleled by a strong 
up-regulation of the expression level of FWD1 due to the transcriptional control of FWD1 by 
the β-catenin/TCF complex (Figure 8). This theoretical finding agrees well with experimental 
observations of increased FWD1 concentration in this cancer type [35, 36, 66]. The 
simulations furthermore demonstrated that even strongly up-regulated FWD1 concentrations 
by up to 17-fold increase could not reduce the elevated β-catenin/TCF steady state 
concentrations under APC mutant conditions (Figure 8). The mutations of APC invincibly 
interfere with the phosphorylation of β-catenin, which is the prerequisite for the β-TrCP 
paralogues to mediate β-catenin degradation. Thus, it is reasonable to assume that 
pharmaceutical up-regulation of either β-TrCP paralogue hardly affects the aberrant 
activation of the Wnt/β-catenin pathway in APC mutation associated cancer. Moreover, the 
β-TrCP paralogues regulate several signalling proteins outside of Wnt/β-catenin signalling, 
such as IκB and Mouse double minute 2 homolog (Mdm2) [24, 25]. Consequently, up-
regulation of HOS and/or FWD1 may induce inappropriate signalling responses in the NF-κB 
and p53 signalling pathways indicating that such an approach generally may not be feasible. 
Besides Wnt/β-catenin signalling, also other signalling pathways were reported to contribute 
to the regulation of HOS and FWD1 expression levels, for instance stress-induced JNK 
signalling, Akt/PKB signalling, and mitogen-activated protein kinase (MAPK) signalling [36, 
39-41]. The model analysis showed that the regulation of HOS or FWD1 concentration by β-
catenin/TCF-independent transcriptional activation modulated the β-catenin/TCF complex 
dynamics (Figure 7, Fig. S2). One may thus speculate that other signalling pathways can 
influence the duration of β-catenin/TCF complex dynamics via transcriptional regulation of 
HOS or FWD1 and, in this way, may co-regulate Wnt/β-catenin target gene expression. 
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Materials and Methods 
4.1 Calculation of steady states and their stability 
Numerical calculation of steady states and their stability as well as simulations of dynamics 
of species were performed using Mathematica 9.0 (Wolfram Research). Steady states are 
calculated by setting the time derivative of each species concentration in the model to zero 
and solving the resulting algebraic equation system for the species concentrations. The 
number of steady states is calculated by counting the steady state solutions that yield non-
negative real values of all species concentrations (Fig. S4). To determine the stability of a 
steady state, the eigenvalues of the Jacobian matrix are calculated [67]. If the real parts of 
all eigenvalues are negative the steady state is asymptotically stable. Otherwise, the steady 
state is called unstable. 
4.2 Definition of signalling time, signal duration, and signal amplitude 
The calculated steady states are used as initial conditions to simulate the continuous 
dynamics of the model species over time. To quantitatively characterise the dynamics of 
species in ODE models, several measures have been introduced (reviewed in [47]). Here, 
three particular measures are considered: signalling time, signal duration, and signal 
amplitude. These three measures may be interpreted to provide information on (i) the 
expected time that the signal needs to arrive at the level of pathway readout (signalling 
time), (ii) the duration of the response at the level of pathway readout (signal duration), 
and (iii) the magnitude of this response (signal amplitude) [48]. The following definitions of 
signalling time (Equation [1]), signal duration (Equation [2]), and signal 
amplitude (Equation [3]) are used that are based on earlier definitions [48, 68, 69]: 
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Doc. S1: The HOS and FWD1 feedback model of Wnt/β-catenin signalling 
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a detailed description of the mathematical model, its equations and parameters, as well as 
Fig. S1: Impact of different combinations of HOS and FWD1 feedback strengths on HOS, 
FWD1, and the β-catenin/TCF complex. 
Fig. S2: Strong transcriptional up-regulation of FWD1 and/or HOS abolishes regulatory 
impact of the feedbacks on β-catenin/TCF dynamics. 
Fig. S3: Impact of the FWD1 feedback strength on β-catenin/TCF steady state for different 
combinations of parameters k7r, k8r, and k17r. 
Fig. S4: Impact of HOS and FWD1 feedback strength on the number and stability of β-
catenin/TCF steady state. 
Table S1: Parameter of the transient Wnt stimulus 
Table S2: Kinetic parameters of the feedback model. 
Table S3: Total protein concentrations of proteins obeying a conservation relation. 
Table S4: Kinetic parameters to model mutations of APC. 
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 Figure 1: Reaction scheme of the Wnt/β-catenin pathway model that includes the FWD1 and 
HOS feedbacks. 
The reaction scheme underlying the published model of Wnt/β-catenin signalling (black; 
reactions 1 - 9 and reactions 11 - 16) is extended by the HOS feedback (green; 
reactions 18 - 21) and FWD1 feedback (blue; reactions 23 - 30). HOS and FWD1 
independently bind to the destruction complex to mediate the ubiquitination of 
phosphorylated β-catenin (reactions 10 and 22, and reactions 10b and 22b, respectively). 
The newly introduced TCF production and degradation are coloured in grey (reactions 31 
and 32, respectively). One-headed arrows denote reactions taking place in the indicated 
direction. Double-headed arrows illustrate reversible binding reactions. Dashed arrows 
represent activation and dashed ‘T’s denote inhibition. Components in a complex are 
separated by a slash. The asterisk marks phosphorylation; ub stands for ubiquitinated 
species. The number next to an arrow specifies the number of the reaction. A detailed 
description of the model is provided in the supplementary Doc. S1. 
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 Figure 2: The feedback model reproduces the differential expression patterns of HOS and 
FWD1. 
(A) Steady state concentrations of HOS (green bars) and FWD1 (blue bars) are calculated in 
the feedback model under wild type and APC mutant “m7” conditions (supplementary 
Doc. S1). HOS and FWD1 feedback strengths are both set to 0.6 nM-1 in the simulations. 
(B) Analysis shown in (A) is extended to HOS and FWD1 feedback strengths both set to 
identical values ranging from 0.1 nM-1 to 6 nM-1 considering APC mutant conditions “m1” to 
“m13”. 
 
 
Figure 3: Variation of either HOS or FWD1 feedback strength allows for the independent 
modulation of HOS or FWD1 expression, respectively. 
(A) HOS feedback strength is gradually increased while FWD1 feedback strength is set to 
zero (scenario I). The steady state concentration of HOS decreases due to increasing HOS 
feedback strength. (B) FWD1 feedback strength is gradually increased while HOS feedback 
strength is set to zero (scenario II). The steady state concentration of FWD1 rises due to 
increasing FWD1 feedback strength. 
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Figure 4: The HOS feedback affects β-catenin/TCF steady state and its dynamics upon Wnt 
stimulation. 
(A) The steady state concentration of the β-catenin/TCF complex responds in a switch-like 
manner to increasing HOS feedback strength. The red lines denote stable steady state 
solutions; the grey dashed line marks unstable solutions. (B, C) Increasing HOS feedback 
strengths increase the signalling time, extend the signal duration, and increase the signal 
amplitude of β-catenin/TCF complex dynamics upon transient Wnt stimulation. The 
dynamics for different HOS feedback strengths are illustrated in (B): HOS feedback strength 
is set to zero (orange), 0.4 nM-1 (red), 0.6 nM-1 (darker red), and 0.8 nM-1 (dark red). 
Quantification of signalling time, signal duration, and signal amplitude of the dynamics for 
different HOS feedback strengths are shown in (C). 
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Figure 5: Changes in the FWD1 feedback strength do not affect β-catenin/TCF steady state 
concentration and dynamics in combination with a HOS feedback strength set to zero. 
(A) The steady state concentration of β-catenin/TCF complex for different FWD1 feedback 
strengths. (B) Overlay of β-catenin/TCF complex dynamics upon transient Wnt stimulation 
comparing the FWD1 feedback strength set to zero (dashed orange) or set to 10 nM-
1
 (dashed dark red). (C) Quantification of signalling time, signal duration, and signal 
amplitude of the dynamics of the β-catenin/TCF complex for different values of the FWD1 
feedback strength. The HOS feedback strength is set to zero in all simulations shown in this 
figure. 
 
 
Figure 6: The FWD1 feedback influences the β-catenin/TCF steady state and its dynamics upon 
Wnt stimulation in combination with high HOS feedback strength. 
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A high HOS feedback strength (60 nM-1) in combination with FWD1 feedback strength set to 
zero leads to a high the steady state concentration of the β-catenin/TCF complex (B, orange 
bar), which is maintained upon transient Wnt stimulation (A). In contrast, if both feedback 
strengths are set to 60 nM-1, the steady state concentration of the β-catenin/TCF complex is 
low (B, dark red bar) and the β-catenin/TCF complex concentration transiently increases 
upon Wnt stimulation (C). 
 
 
 
Figure 7: β-Catenin/TCF independent up-regulation of FWD1 or HOS concentration affects β-
catenin/TCF dynamics upon Wnt stimulation. 
(A) Different dynamics of the β-catenin/TCF complex upon transient Wnt stimulation for 
selected combinations of FWD1 and HOS mRNA production rates. Red: HOS and FWD1 
production rates of 10-6 nM·min-1 (reference case); dark red: HOS and FWD1 production 
rates of 10-6 nM·min-1 and 5·10-6 nM·min-1, respectively; orange: HOS and FWD1 production 
rates of 5·10-6 nM·min-1 and 10-6 nM·min-1, respectively. (B) Quantification of signalling time, 
signalling duration, and signal amplitude of the dynamics of the β-catenin/TCF complex upon 
transient Wnt stimulation for different values of FWD1 mRNA production rate (dark red lines) 
or HOS mRNA production rate (orange lines). The HOS and FWD1 feedback strengths are 
both set to 0.6 nM-1 in all simulations. 
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Figure 8: The FWD1 feedback mechanism does not protect against up-regulation of β-
catenin/TCF concentrations induced by APC mutations. 
(A) The steady state concentration of the β-catenin/TCF complex increases in APC 
truncation mutants “m1” to “m13” with respect to wild type conditions in the case of FWD1 
feedback strength set to zero and HOS feedback strength ranging from 0.1 nM-1 to 1 nM-1. 
(B) β-catenin/TCF steady state concentrations of wild type cells and APC mutants “m1” to 
“m13” for FWD1 and HOS feedback strengths both set to identical values ranging from 
0.1 nM-1 to 6 nM-1.  (C) FWD1 steady state concentrations increase in APC mutants “m1” to 
“m13” with respect to wild type conditions. FWD1 and HOS feedback strengths are both set 
to identical feedback strengths ranging from 0.1 nM-1 to 6 nM-1.  (D) Fold increase of FWD1 
steady state concentrations with respect to wild type is shown. This fold increase hardly 
changes for FWD1 and HOS feedback strengths set to identical values ranging from 0.1 nM-
1
 to 6 nM-1. However, differences can be seen between wild type and APC mutants. 
F 
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igure 9: Simulations of suggested experiments to validate model predictions. 
(A) Proposed experimental setup to validate a switch-like response of β-catenin/TCF steady 
state concentrations upon changes in HOS feedback strength in combination with FWD1 
feedback set to zero (Figure 4A). CRD-BP knock-out cells may represent the modelling 
scenario of FWD1 feedback set to zero. These cells contain low levels of β-catenin/TCF 
complex. Knock-down of HOS in CRD-BP knock-out cells will increase β-catenin/TCF 
complex concentrations. Application of increasing amounts of decoy oligonucleotides will 
reduce HOS feedback strength leading to a sudden switch-like reduction of β-catenin/TCF 
complex concentrations as predicted in Figure 4A. (B) Proposed experimental setup to test 
the different functions of the FWD1 and HOS feedback mechanisms. In wild type 
cells (bars 1-3), knock-out of FWD1 or HOS will not increase β-catenin/TCF steady state 
concentrations. Similarly, knock-out of FWD1 does not affect β-catenin/TCF concentrations 
in CRD-BP knock-out cells (bars 4 and 5). In contrast, knock-out of HOS strongly increases 
β-catenin/TCF concentrations in CRD-BP knock-out cells (bar 6). The model predicts that 
HOS and CRD-BP double knock-out (bar 6) increases β-catenin/TCF concentrations to 
similar extends as predicted under APC mutant “m9” conditions (bars 7-9). Corresponding 
example cell lines of APC mutant “m9” might be SW480 or SW620 cells, as they harbour 
truncations at codon 1338 [66]. Other cell lines representing APC mutants “m1” to “m8” may 
be constructed by transfecting truncated APC expression constructs in SW480 cells as has 
been previously described [43, 70]. 293T cells could potentially serve as “wild type” since to 
our knowledge no mutations of destruction complex components have been reported in this 
cell line. 
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